Foghorn Therapeutics (FHTX) Total Liabilities (2019 - 2026)

Foghorn Therapeutics' Total Liabilities history runs 8 years deep, the most recent figure standing at $298.6 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 6.8% year-over-year to $298.6 million; the TTM figure through Mar 2026 stood at $298.6 million (down 6.8% YoY), while the FY2025 annual figure was $306.6 million, down 6.95% from the prior year.
• Total Liabilities for Q1 2026 stood at $298.6 million, down from $306.6 million in the prior quarter.
• The five-year high for Total Liabilities was $415.9 million in Q1 2022, with the low at $294.6 million in Q3 2025.
• The 5-year median for Total Liabilities is $352.5 million (2024), against an average of $355.6 million.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities soared 297.15% in 2022, then declined 12.49% in 2025.
• Foghorn Therapeutics' Total Liabilities stood at $404.8 million in 2022, then declined by 10.29% to $363.1 million in 2023, then retreated by 9.25% to $329.5 million in 2024, then decreased by 6.95% to $306.6 million in 2025, then declined by 2.62% to $298.6 million in 2026.
• Business Quant data shows FHTX's Total Liabilities at $298.6 million in Q1 2026, $306.6 million in Q4 2025, and $294.6 million in Q3 2025.